{"id":56366,"date":"2023-05-01T11:03:07","date_gmt":"2023-05-01T09:03:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/hidradenitis-suppurativa-global-market-to-2030-increased-disposable-income-fuels-the-sector-researchandmarkets-com\/"},"modified":"2023-05-01T11:03:07","modified_gmt":"2023-05-01T09:03:07","slug":"hidradenitis-suppurativa-global-market-to-2030-increased-disposable-income-fuels-the-sector-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/hidradenitis-suppurativa-global-market-to-2030-increased-disposable-income-fuels-the-sector-researchandmarkets-com\/","title":{"rendered":"Hidradenitis Suppurativa Global Market to 2030: Increased Disposable Income Fuels the Sector – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Hidradenitis Suppurativa Market: Analysis By Patients, By Drugs (Povorcitinib, Bimekizumab, Sonelokimab), By Region Size (The US, Europe, Rest of the World) & Forecast with Impact Analysis of COVID-19 and Forecast up to 2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.<\/p>\n

<\/a><\/p>\n

\nIn 2022, the global hidradenitis suppurativa market was valued at US$1.46 billion, and is probable to reach US$2.24 billion by 2030.<\/p>\n

\nHidradenitis Suppurativa, according to the National Organization of Rare Disorders, is a chronic disorder characterized by swelling, painful lesions in the armpit, groin, anal, and breast regions. It is a painful and long-term skin ailment that causes abscesses and scars.<\/p>\n

\nPatients with this ailment may present with acute abscesses, but it frequently evolves to a chronic state with persistent discomfort, sinus tract fistula formation, and scarring. Disease severity is stratified using the Hurley staging system: Stage I involves abscess formation without sinus tracts or scarring; Stage II involves recurrent abscesses with sinus tracts and scarring; and Stage III involves diffuse or multiple interconnected sinus tracts and abscesses.<\/p>\n

\nThe only FDA-approved treatment for HS is AbbVie’s anti-TNF antibody Humira (adalimumab). The drug was approved based on results from two pivotal Phase III studies (POINEER I and PIONEER II), in which 633 patients (n=307 in PIONEER I and n=326 in PIONEER 2) with moderate to severe HS were randomized to receive Humira or placebo weekly in addition to daily topical antiseptic.<\/p>\n

\nTechnology advanced treatments such as laser surgeries would boost hidradenitis suppurativa treatment market growth in the near future. Furthermore, FDA approvals for drugs delivery and clinical trials are propelling the hidradenitis suppurativa market growth. The global hidradenitis suppurativa market is projected to grow at a CAGR of 5.50%, during the forecast period of 2023-2030.<\/p>\n

\nKey Attributes:<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Report Attribute<\/strong><\/td>\nDetails<\/strong><\/td>\n<\/tr>\n
No. of Pages<\/td>\n106<\/td>\n<\/tr>\n
Forecast Period<\/td>\n2023 – 2030<\/td>\n<\/tr>\n
Estimated Market Value (USD) in 2023<\/td>\n$1.54 Billion<\/td>\n<\/tr>\n
Forecasted Market Value (USD) by 2030<\/td>\n$2.24 Billion<\/td>\n<\/tr>\n
Compound Annual Growth Rate<\/td>\n5.5%<\/td>\n<\/tr>\n
Regions Covered<\/td>\nGlobal<\/td>\n<\/tr>\n<\/table>\n

\nMarket Dynamics<\/strong><\/p>\n

\nGrowth Drivers<\/strong><\/em><\/p>\n